PF-07985045 + fluorouracil + oxaliplatin + leucovorin + bevacizumab

This is a combination regimen consisting of five agents: - **PF-07985045**: An investigational oral inhibitor of the KRAS pathway, developed to target KRAS-mutant solid tumors by inhibiting oncogenic KRAS signaling, thereby reducing tumor cell growth and proliferation. KRAS mutations are present in a sizable proportion of solid tumors, including colorectal, pancreatic, and non-small cell lung cancers[4][1][2]. - **Fluorouracil (5-FU)**: A small molecule antimetabolite/antineoplastic agent that inhibits thymidylate synthase, blocking DNA synthesis and function. - **Oxaliplatin**: A platinum-based small molecule chemotherapeutic that forms DNA crosslinks, disrupting DNA replication and transcription, resulting in cell death. - **Leucovorin (folinic acid)**: A reduced folate used to enhance the efficacy and reduce the toxicity of 5-FU by increasing thymidylate synthase inhibition. - **Bevacizumab**: A monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thus depriving tumors of their blood supply. This regimen is being studied for safety and efficacy in advanced solid tumors, particularly in patients with **KRAS-mutated** colorectal, pancreatic, and non-small cell lung cancers, often after standard therapy failure. The combination aligns with regimens like FOLFOX plus bevacizumab, but uniquely includes the novel agent PF-07985045, which is in early-phase clinical trials and not yet FDA approved[1][2][5][4][3].

Other names

5-FU + oxaliplatin + leucovorin + bevacizumab + PF-07985045PF-07985045 + FOLFOX + bevacizumab